salicylic acid has been researched along with Mucocutaneous Lymph Node Syndrome in 4 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Mucocutaneous Lymph Node Syndrome: An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-keto-prostaglandin F1 alpha (PGF1 alpha) levels were compared before enrollment and on days 4, 7 and 14 of treatment." | 5.07 | Salicylate treatment in Kawasaki disease: high dose or low dose? ( Akagi, T; Inoue, O; Kato, H; Sato, N, 1991) |
| "We described the pharmacokinetics of acetylsalicylic acid and salicylic acid in 5 children with prior Kawasaki disease receiving buffered aspirin tablets or intravenous aspirin DL-lysine." | 3.68 | Disposition of single-dose intravenous and oral aspirin in children. ( Ito, S; Oka, R; Tsuchida, A; Yoshioka, H, 1991) |
| "8 years (range 8 months to 8 years), who had Kawasaki disease treated with acetylsalicylic acid (ASA) 30 to 180 mg/kg." | 3.67 | Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease. ( Koren, G; MacLeod, SM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, PK | 1 |
| Yanagihara, R | 1 |
| Melish, ME | 1 |
| Nerurkar, VR | 1 |
| Koren, G | 1 |
| MacLeod, SM | 1 |
| Ito, S | 1 |
| Oka, R | 1 |
| Tsuchida, A | 1 |
| Yoshioka, H | 1 |
| Akagi, T | 1 |
| Kato, H | 1 |
| Inoue, O | 1 |
| Sato, N | 1 |
1 trial available for salicylic acid and Mucocutaneous Lymph Node Syndrome
| Article | Year |
|---|---|
Salicylate treatment in Kawasaki disease: high dose or low dose?
Topics: 6-Ketoprostaglandin F1 alpha; Alanine Transaminase; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
3 other studies available for salicylic acid and Mucocutaneous Lymph Node Syndrome
| Article | Year |
|---|---|
Modulation of adhesion molecules and monocyte chemoattractant protein by tumor necrosis factor-alpha and salicylic acid in primary human coronary artery endothelial cells.
Topics: Cell Adhesion Molecules; Cells, Cultured; Coronary Vessels; Endothelial Cells; Humans; Monocyte Chem | 2003 |
Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Mu | 1984 |
Disposition of single-dose intravenous and oral aspirin in children.
Topics: Absorption; Administration, Oral; Aspirin; Biological Availability; Buffers; Child, Preschool; Drug | 1991 |